Sunday, August 17, 2014
In October, I will be visiting China for the first time to appear at a Global Conference on Corruption in Jinan. I have come to corruption through the backdoor of writing about whistleblowing legislation in the U.S. and am still getting my feet wet. Building on my prior work, I am interested in exploring corruption law from the perspective of prosecutorial discretion. While public concern with corruption has grown world wide during the past twenty years, prosecution has been selective.
Right now, concerns with bribes in the health care and pharmaceutical industries have moved to the forefront. Just last week, Syria announced that it is investigating claims that representatives from GlaxoSmithKline bribed Syrian doctors to boost sales of medicines. These new allegations follow allegations in China last year in which four GSK executives allegedly evaded the company's internal control systems in an effort to boost sales.
As my research continues, I hope to discover why certain industries either seem prone to corruption or are prone to investigation.
Scott Campbell, "Glaxo China Bribery Allegations-Timeline," THE TELEGRAPH, May 14, 2014.
"GlaxoSmith Kline Faces Bribery Claims in Syria," THE TELEGRAPH, August 12, 2014.